Biocon Biologics partners with Voluntis for digital therapeutics for diabetics patients

The licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis will allow Biocon Biologics to offer therapeutic product #39;Insulia#39; to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement.

from Moneycontrol Business News https://ift.tt/2DYWkMx